Liquid Biopsy MarketThe global liquid biopsy market is poised for substantial expansion, with an estimated revenue of USD 1,538.3 million in 2023. The market is projected to grow at an impressive ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung ...

As our understanding of cancer has evolved, so too has the promise of personalized oncology — treatment tailored to each ...

On World Cancer Day, it is essential to spread awareness about how emerging technologies are transforming cancer care and the ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

An ultrasensitive blood test detecting low levels of ctDNA could help to improve disease stratification in early-stage lung adenocarcinoma.

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...